A ginseng-family extract sped diabetic wound healing by protecting macrophage mitochondria — in lab models

Diabetic foot ulcers are among the most feared complications of diabetes, and their failure to heal is partly a mitochondrial story: persistent hyperglycemia disrupts metabolism, prolongs inflammation and damages the macrophages that coordinate repair. A study by Chen, Zhu, Sun and Hou in Food Science & Nutrition (2026) tested whether saponins from Panax notoginseng — a ginseng relative used in traditional medicine — could interrupt that stall.

What happened in the diabetic mice?

Diabetes was induced in male mice with streptozotocin, followed by a 6-millimeter full-thickness wound. Oral PNS accelerated closure dose-dependently, with smaller epithelial gaps, less inflammatory infiltration and greater collagen deposition — without significantly changing body weight or random blood glucose (glucose- and insulin-tolerance tests did improve). Inside the wounds, pro-inflammatory (iNOS-positive) macrophages fell, reparative (Arg1-positive) macrophages rose, inflammatory cytokines IL-1beta, IL-6 and IL-18 fell, and electron microscopy showed fewer swollen, abnormal mitochondria, with dynamics shifted from fission (lower DRP1 activation) toward fusion (higher mitofusin 1/2 and OPA1).

How did the team pin the mechanism on 11,12-EET?

Untargeted metabolomics flagged the lipid mediator 11,12-EET, which is degraded by soluble epoxide hydrolase (encoded by Ephx2). PNS reversed Ephx2 expression in stressed macrophages and restored 11,12-EET; a soluble-epoxide-hydrolase inhibitor (TPPU) reproduced PNS's effects without adding to them, while an 11,12-EET antagonist (14,15-EEZE) abolished PNS's protection of mitochondrial shape, membrane potential and wound closure — the classic pattern for a shared pathway. In a public human single-cell dataset, macrophages from non-healing diabetic foot ulcers expressed more Ephx2 than healthy skin, a nonexperimental but directionally consistent human signal. Each of the five main saponins also worked individually in mice, with effects comparable to the metformin control — a comparison the authors stress does not establish clinical equivalence.

What stands between this and a wound treatment?

Everything clinical. The work centers on macrophages while healing also needs keratinocytes, fibroblasts and blood vessels; the pharmacological tools can have off-target effects and no genetic knockouts were done; and ginsenosides are poorly absorbed orally, so gut-microbe metabolites may do part of the work. Nothing here supports buying notoginseng supplements for a diabetic wound — ulcers need medical care, and this mechanism is a research lead, not a remedy.

Where the evidence stands

• Established: Diabetic wounds involve prolonged macrophage-driven inflammation, NLRP3 inflammasome activation and mitochondrial damage; no botanical extract is an established diabetic wound therapy.
• Preliminary: In diabetic mice and cultured macrophages (Food Science & Nutrition, 2026), oral Panax notoginseng saponins accelerated wound closure dose-dependently, preserved 11,12-EET via Ephx2 suppression, reduced mitochondrial swelling and pyroptosis markers, and increased collagen; inhibitor/antagonist experiments supported the pathway, and human ulcer dataset macrophages showed higher Ephx2.
• Absent: Human trials, pharmacokinetics and safety data for PNS in wound healing, and proof the mechanism operates in patients.